Nivolumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
CURATE.AI - a small data, AI-derived technology platform - allows personalised guidance of an
individual's dose modulations based only on that individual's data. Additionally, CURATE.AI
is mechanism-independent, and dynamically adapts to changes experienced by the subject,
providing dynamic dose optimisation throughout the duration of the subject's treatment. This
study aims to demonstrate the feasibility of applying CURATE.AI in standard of care settings
for treatment of solid tumours with Nivolumab. An additional objective is to explore
sequential ctDNA measurements as a response marker collected at a higher frequency of
probing, with modulated doses.